From a therapeutic point of view, the fluctuating kinetics of GLI1 levels following a DYRK1B inhibition are problematic as suboptimal or short-term treatments with DYRK1B antagonists might result in concomitant upregulation of oncogenic GLI1 in cancer cells. Here, DYRK1B is linked to cancer.